Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.imlet.2022.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overlapping GAD65-associated autoimmune neurological syndromes and type 1 diabetes.
Immunol Lett
April 2022
Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, In der Schornau 23-25, Bochum, 44892 Germany. Electronic address:
Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.
Neurol Neuroimmunol Neuroinflamm
May 2020
From the Department of Neurology (A.M.-L., M.A.A.M.d.B., A.E.M.B., M.M.P.N., E.S.P.H., A.J.W.B., R.F.N., J.M.d.V., P.A.E.S.S., M.J.T.) and Department of Immunology (S.B., M.W.J.S.), Erasmus MC University Medical Center; Department of Neurology (A.M.-L.), IDIBAPS, Barcelona, Spain; and Health Care Provider of the European Reference Network on Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA) (M.J.T.), Rotterdam, the Netherlands.
Article Synopsis
- The study investigated the clinical characteristics and treatment responses of 56 patients with positive antibodies against glutamic acid decarboxylase 65 (anti-GAD65), focusing on their neurologic symptoms and immunotherapy outcomes.
- Among patients with high concentrations of anti-GAD65 (over 10,000 IU/mL), a majority exhibited classical syndromes like stiff-person syndrome and cerebellar ataxia, showing a 70% improvement rate with immunotherapy, though none achieved complete recovery.
- Patients with low anti-GAD65 concentrations presented a wider variety of symptoms, suggesting the need for alternative diagnostic approaches due to their less typical clinical features.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!